FDA Ad Division Will Increase Focus On Outcomes Claims After Reorganization
FDA's reorganized Division of Drug Marketing, Advertising & Communication will be increasing its focus on promotions based on outcomes data, Division Director Tom Abrams said during the Drug Information Association's annual meeting in Chicago June 18
You may also be interested in...
FDA's Division of Drug Marketing, Advertising & Communications is reorganizing its enforcement and review staff into health professional and consumer review groups
FDA development of guidances for including quality of life claims in drug labeling and promotions and for formulary-directed pharmacoeconomic information is on hold until more information is collected.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011